For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of imaging-based progression-free survival compared with a control medication, according ...
Feb 17, 2023
0
17
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC). ...
Sep 20, 2021
0
8
More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance ...
May 10, 2021
0
21
A study published today in Nature Communications shows that the drug rucaparib has been effective in treating certain types of ovarian cancers if used early in treatment, after a diagnosis, and before the cancer cells build ...
May 4, 2021
0
32
A targeted treatment for advanced ovarian cancer has been approved for use on the NHS in England and will be paid for by the Cancer Drugs Fund.
Oct 14, 2019
0
3
A targeted drug with potential to slow the progress of ovarian cancer has been rejected for use on the NHS in England.
Aug 12, 2019
0
12
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, ...
Apr 2, 2019
0
1
